Diadem, a company developing the first blood-based test for the prediction of early onset Alzheimer’s disease, announced that Paul Kinnon has been named Chief Executive Officer.
Mr. Kinnon brings Diadem extensive global executive experience in successfully developing and commercializing innovative diagnostic and life science technologies in Europe and the U.S.
Diadem’s transformational technology for the first time makes it possible to diagnose Alzheimer’s early in the disease process and to predict whether the disease will progress. This will allow patients to seek treatment at a time when it is still possible to impact disease progression and preserve function.